Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region

Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the registration and marketing of Lutrate 1 month (leuprolide acetate 3.75mg), Spain-based GP Pharm’s leading anti-cancer compound, for the Middle East and North Africa (MENA) region. The drug is a hormonal androgen deprivation therapy to prevent tumor growth in patients with advanced prostate cancer.

Under the terms of the accord, Hikma will have the licensing rights to register, market and distribute Lutrate 1 month in 23 countries across MENA. Hikma will also become the partner of choice in the MENA region for GP Pharm’s pipeline of oncology products. No financial terms of the deal were disclosed.

Mazen Darwazah, Hikma’s vice chairman and chief executive of MENA, said: “Hikma is committed to improving the treatment of cancer in the region through the development of our oncology product portfolio. We are pleased to be licensing this innovative injectable treatment, which has excellent potential and complements our portfolio and pipeline. It is in line with Hikma’s aim to deliver a reliable supply of high quality pharmaceutical products to MENA that reduce patients’ dependency on a single source for treatment.”